IL135602A0 - Determination of cellular growth abnormality - Google Patents

Determination of cellular growth abnormality

Info

Publication number
IL135602A0
IL135602A0 IL13560298A IL13560298A IL135602A0 IL 135602 A0 IL135602 A0 IL 135602A0 IL 13560298 A IL13560298 A IL 13560298A IL 13560298 A IL13560298 A IL 13560298A IL 135602 A0 IL135602 A0 IL 135602A0
Authority
IL
Israel
Prior art keywords
proteins
determination
growth abnormalities
cellular growth
cancerous
Prior art date
Application number
IL13560298A
Other languages
English (en)
Original Assignee
Cancer Res Campaign Tech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9722217.8A external-priority patent/GB9722217D0/en
Priority claimed from GBGB9724134.3A external-priority patent/GB9724134D0/en
Priority claimed from GBGB9804156.9A external-priority patent/GB9804156D0/en
Priority claimed from GBGB9810560.4A external-priority patent/GB9810560D0/en
Priority claimed from GBGB9817075.6A external-priority patent/GB9817075D0/en
Application filed by Cancer Res Campaign Tech filed Critical Cancer Res Campaign Tech
Publication of IL135602A0 publication Critical patent/IL135602A0/xx

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5755—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the uterine cervix, uterine corpus or endometrium
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57595—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving intracellular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)
  • Electrotherapy Devices (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)
  • Eye Examination Apparatus (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Liquid Crystal Substances (AREA)
IL13560298A 1997-10-21 1998-10-21 Determination of cellular growth abnormality IL135602A0 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GBGB9722217.8A GB9722217D0 (en) 1997-10-21 1997-10-21 Determination of cellular growth abnormality
GBGB9724134.3A GB9724134D0 (en) 1997-11-14 1997-11-14 Determination of cellular growth abnormality
GBGB9804156.9A GB9804156D0 (en) 1998-02-26 1998-02-26 Determination of cellular growth abnormality
GBGB9810560.4A GB9810560D0 (en) 1998-05-15 1998-05-15 Determination of cellular growth abnormality
GBGB9817075.6A GB9817075D0 (en) 1998-08-05 1998-08-05 Determination of cellular growth abnormality
PCT/GB1998/003153 WO1999021014A1 (en) 1997-10-21 1998-10-21 Determination of cellular growth abnormality

Publications (1)

Publication Number Publication Date
IL135602A0 true IL135602A0 (en) 2001-05-20

Family

ID=27517431

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13560298A IL135602A0 (en) 1997-10-21 1998-10-21 Determination of cellular growth abnormality

Country Status (23)

Country Link
EP (1) EP1025444B1 (de)
JP (2) JP2000511291A (de)
CN (1) CN1282422A (de)
AT (1) ATE290213T1 (de)
AU (1) AU751754B2 (de)
BR (1) BR9813127A (de)
CA (1) CA2305872C (de)
CO (1) CO5080817A1 (de)
DE (1) DE69829198T2 (de)
DK (1) DK1025444T3 (de)
ES (1) ES2239407T3 (de)
GB (1) GB2332515B (de)
HU (1) HUP0004134A2 (de)
IL (1) IL135602A0 (de)
IS (1) IS5456A (de)
MA (1) MA26557A1 (de)
NO (1) NO20002044L (de)
NZ (1) NZ503996A (de)
PE (1) PE20000121A1 (de)
PL (1) PL340057A1 (de)
PT (1) PT1025444E (de)
SK (1) SK5592000A3 (de)
WO (1) WO1999021014A1 (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6361954B1 (en) 1996-05-02 2002-03-26 Cold Spring Harbor Laboratory Methods of immunoassay for human CDC6
GB0018140D0 (en) * 2000-07-24 2000-09-13 Medical Res Council Screening for abnormalities
DE10063179A1 (de) * 2000-12-18 2002-06-20 Bayer Ag Verfahren zur spezifischen Detektion von Tumorzellen und ihren Vorstufen in Gebärmutterhalsabstrichen durch simultane Messung von mindestens zwei verschiedenen molekularen Markern
DE10063112A1 (de) 2000-12-18 2002-06-20 Bayer Ag Verfahren zur Erhöhung der klinischen Spezifität bei der Detektion von Tumoren und ihren Vorstufen durch simultane Messung von mindestens zwei verschiedenen molekularen Markern
NZ528205A (en) 2001-03-12 2006-09-29 Monogen Inc Cell-based detection and differentiation of disease status in a cytological sample using a panel comprising a plurality of probes
EP1369694A1 (de) 2002-04-09 2003-12-10 MTM Laboratories AG Verfahren zur Unterscheidung zwischen Metaplasien und neoplastischen oder präneoplastischen Läsionen
JP2006514823A (ja) * 2002-08-20 2006-05-18 ミレニアム ファーマスーティカルズ インク 子宮頸癌の同定、評価、予防および治療を行うための組成物、キットおよび方法
EP1422526A1 (de) 2002-10-28 2004-05-26 MTM Laboratories AG Verfahren zur verbesserten Diagnose von Dysplasien
JP2006521794A (ja) * 2003-02-14 2006-09-28 スミスクライン・ビーチャム・コーポレイション Ｋｓｐ発現と相関関係にある示差発現核酸
US7361460B2 (en) 2003-04-11 2008-04-22 Digene Corporation Approach to molecular diagnosis of human papillomavirus-related diseases
US20070122909A1 (en) * 2003-10-20 2007-05-31 Syssmex Corporation Method of treating cells
ATE549625T1 (de) 2004-03-24 2012-03-15 Tripath Imaging Inc Verfahren und zusammensetzungen zum nachweis einer zervixerkrankung
US7595380B2 (en) * 2005-04-27 2009-09-29 Tripath Imaging, Inc. Monoclonal antibodies and methods for their use in the detection of cervical disease
GB0518877D0 (en) * 2005-09-15 2005-10-26 Medical Res Council Markers and methods
US7632498B2 (en) 2005-12-19 2009-12-15 Tripath Imaging, Inc. MCM6 and MCM7 monoclonal antibodies and methods for their use in the detection of cervical disease
EP2487258B1 (de) 2006-01-05 2014-10-01 The Ohio State University Research Foundation Verfahren auf Mikro-RNA-Basis zur Diagnose von Darmkrebs, Bauchspeicheldrüsenkrebs und Magenkrebs
ES2446362T3 (es) 2006-03-20 2014-03-07 The Ohio State University Research Foundation Huellas de microARN durante megacariocipoyesis humana
DE102006020852A1 (de) 2006-05-04 2007-11-15 Robert Bosch Gmbh Gasdruckbehälter für gasbetriebene Kraftfahrzeuge
JP2010535473A (ja) 2007-08-03 2010-11-25 ズィ、オハイオウ、ステイト、ユーニヴァーサティ、リサーチ、ファウンデイシャン ｎｃＲＮＡをコードする超保存領域
GB0811567D0 (en) * 2008-06-24 2008-07-30 Cytosystems Ltd Assay
US8916533B2 (en) 2009-11-23 2014-12-23 The Ohio State University Materials and methods useful for affecting tumor cell growth, migration and invasion
GB0921873D0 (en) * 2009-12-15 2010-01-27 Cytosystems Ltd Assay
JP5931897B2 (ja) 2010-11-12 2016-06-08 ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイションＴｈｅ Ｏｈｉｏ Ｓｔａｔｅ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ マイクロｒｎａ−２１、ミスマッチ修復および結腸直腸癌に関連する物質および方法
CA2817982C (en) 2010-11-15 2020-06-30 The Regents Of The University Of Michigan Controlled release mucoadhesive systems
WO2012090479A1 (en) * 2010-12-28 2012-07-05 Oncotherapy Science, Inc. Mcm7 as a target gene for cancer therapy and diagnosis
AU2012323924A1 (en) 2011-10-14 2014-05-29 The Ohio State University Methods and materials related to ovarian cancer
CA2859430A1 (en) 2011-12-13 2013-06-20 Ohio State Innovation Foundation Methods and compositions related to mir-21 and mir-29a, exosome inhibition, and cancer metastasis
EP2800821B1 (de) * 2012-01-05 2016-11-16 Centre National de la Recherche Scientifique (CNRS) Signatur zur diagnose von krebsaggressivität
US8859202B2 (en) 2012-01-20 2014-10-14 The Ohio State University Breast cancer biomarker signatures for invasiveness and prognosis
US11306364B2 (en) 2012-02-18 2022-04-19 Duke University TERT promoter mutations in gliomas and a subset of tumors
US10711310B2 (en) * 2013-02-18 2020-07-14 Duke University Tert promoter mutations in gliomas and a subset of tumors
GB201412731D0 (en) * 2014-07-17 2014-09-03 Immunocore Ltd & Adaptimmune Ltd Peptides
AU2016261279B2 (en) * 2015-05-10 2020-12-10 Ventana Medical Systems, Inc. Compositions and methods for simultaneous inactivation of alkaline phosphatase and peroxidase enzymes during automated multiplex tissue staining assays
CN107771285A (zh) 2015-06-08 2018-03-06 阿奎尔诊断有限公司 方法
EP4060344A1 (de) 2015-06-08 2022-09-21 Arquer Diagnostics Limited Verfahren und kits
GB201509907D0 (en) * 2015-06-08 2015-07-22 Urosens Ltd Antibodies
GB201511196D0 (en) 2015-06-25 2015-08-12 Cytosystems Ltd Monoclonal antibodies
JP6245299B2 (ja) * 2016-04-27 2017-12-13 バクスアルタ ゲーエムベーハー 組換え安定細胞クローン、その産生およびその使用
CN106636343B (zh) * 2016-11-04 2021-03-19 深圳大学 一种检测口腔癌的标志物及其试剂盒
GB201820867D0 (en) * 2018-12-20 2019-02-06 Arquer Diagnostics Ltd Detection method
CN115453108B (zh) * 2019-12-11 2025-08-08 广东菲鹏生物有限公司 用于免疫诊断试剂中固相载体的封闭阶段处理剂及应用和产品

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0157613A3 (de) * 1984-03-30 1987-09-30 Syntex (U.S.A.) Inc. Monoklonale Antikörper spezifisch für menschliche Basalzellen und bösartige schuppenartige Zellproteine, Hybridome, Bösartigkeitstestverfahren und diagnostische Reagenssätze
US5851821A (en) * 1996-05-02 1998-12-22 Cold Spring Harbor Laboratory DNA Replication-regulating genes
EP0812594A1 (de) * 1996-06-13 1997-12-17 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Verbindungen die interferieren mit DNS Replikation in schnell proliferierenden Zellen zur Verwendung in der Krebstherapie und Verfahren zur Identifizierung solcher Substanzen
US5858683A (en) * 1996-08-30 1999-01-12 Matritech, Inc. Methods and compositions for the detection of cervical cancer

Also Published As

Publication number Publication date
CO5080817A1 (es) 2001-09-25
MA26557A1 (fr) 2004-12-20
IS5456A (is) 2000-04-17
JP3774196B2 (ja) 2006-05-10
EP1025444A1 (de) 2000-08-09
NZ503996A (en) 2002-04-26
NO20002044D0 (no) 2000-04-18
AU751754B2 (en) 2002-08-29
DE69829198T2 (de) 2006-01-12
DE69829198D1 (de) 2005-04-07
EP1025444B1 (de) 2005-03-02
JP2003240786A (ja) 2003-08-27
CA2305872A1 (en) 1999-04-29
NO20002044L (no) 2000-06-07
HUP0004134A2 (en) 2001-03-28
CA2305872C (en) 2008-02-19
DK1025444T3 (da) 2005-06-27
WO1999021014A1 (en) 1999-04-29
ES2239407T3 (es) 2005-09-16
PT1025444E (pt) 2005-07-29
SK5592000A3 (en) 2000-10-09
GB9823069D0 (en) 1998-12-16
PE20000121A1 (es) 2000-02-17
GB2332515A (en) 1999-06-23
ATE290213T1 (de) 2005-03-15
GB2332515B (en) 1999-12-15
AU9550298A (en) 1999-05-10
PL340057A1 (en) 2001-01-15
BR9813127A (pt) 2000-08-15
JP2000511291A (ja) 2000-08-29
CN1282422A (zh) 2001-01-31

Similar Documents

Publication Publication Date Title
GB2332515B (en) Determination of cellular growth abnormality
Vercoutter-Edouart et al. Proteomic analysis reveals that 14-3-3σ is down-regulated in human breast cancer cells
Canaani et al. Altered transcription of an oncogene in chronic myeloid leukaemia
Bostwick Natural history of early bladder cancer
CA2166292A1 (en) Assay for ykl-40 as a marker for degradation of mammalian connective tissue matrices
WO1998010069A3 (en) E25a protein, methods for production and use thereof
BR0315666A (pt) Dna de a34 e a33 do tipo 3, proteìnas, seus anticorpos e métodos de tratamento usando os mesmos
CA2487048A1 (en) Method for solution based diagnosis
AU2006200645B2 (en) Nuclear matrix protein alterations associated with colon cancer and colon metastasis to the liver, and uses thereof
SE9500023D0 (sv) Method of detecting cancer
AU2003214909A1 (en) Nuclear matrix protein alterations associated with colon cancer and colon metastasis to the liver, and uses thereof
Rupp et al. Brushing cytology in biliary tract obstruction
DK0566571T3 (da) Diagnose af metastatisk cancer ved hjælp af mts-1-genet
EA200000845A1 (ru) Ген, кодирующий новый маркер рака
Reis-Filho et al. p63 expression in sarcomatoid/metaplastic carcinomas of the breast.
Rumilla et al. Galectin-4 expression in carcinoid tumors
AR014382A1 (es) Determinacion de anormalidad en el crecimiento celular
EP2075582A3 (de) Neuartiges Tumor-Antigen zur Diagnose und Therapie von Blasen-, Eierstock-, Lungen-, und Nierenkrebs
TH41035A (th) การกำหนดของความผิดปกติในการเจริญเติบโตของเซลล์
Gupta et al. Tissue isoantigens A, B, and H in carcinoma of the cervix uteri: their clinical significance
Tateishi et al. DNA polymerase‐α as a putative early relapse marker in non‐small cell lung cancer. An immunohistochemical study
Yildirim et al. Significance of p53 and bcl-2 immunoexpression in the prognosis of laryngeal squamous cell carcinoma
Wundrack et al. PCR Expression Analysis Of the Estrogeninducible Gene Bcei in Gastrointestinal and Other Human Tumors
EP1243653A3 (de) E25a Protein, Methoden zur Herstellung und Verwendung
Freeman Potential clinical applications of antibodies against the minichromosome maintenance (MCM) proteins